Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H32N2O2 |
Molecular Weight | 320.4696 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1
InChI
InChIKey=RYOOHIUJEJZCFT-UHFFFAOYSA-N
InChI=1S/C19H32N2O2/c1-5-21(6-2)14-13-20-18(17-10-8-7-9-11-17)19(22)23-15-12-16(3)4/h7-11,16,18,20H,5-6,12-15H2,1-4H3
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ijrcog.org/index.php/ijrcog/article/view/1419
Curator's Comment: Description was created based on several sources, including http://www.ijrcog.org/index.php/ijrcog/article/view/1419
Camylofin is an antimuscarinic. This medication is used as antispasmodic in biliary colic, renal and ureteric colic, dysmenorrhoea, peptic ulcer and chronic enterocolitis. It is used to treat stomach ache in infants and children. Camylofin should be the first choice and may be preferred over other drugs for cervical dilatation and acceleration of active phase of labor.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14831430
Curator's Comment: refernce retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13331655
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D07076 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ANAFORTAN Approved UseCamylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity. |
|||
Primary | ANAFORTAN Approved UseCamylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity. |
PubMed
Title | Date | PubMed |
---|---|---|
[Pharmacology of Avacan]. | 1951 Apr 6 |
|
A study of metabolism of isoamyl alpha-[N-(beta-diethylamino-ethyl)]-aminophenylacetate (avacan). | 1956 Mar |
|
Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. | 2007 Jan-Feb |
|
Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis. | 2010 Sep |
|
Antispasmodics for labour. | 2012 Aug 15 |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA03DA05
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
||
|
WHO-VATC |
QA03AA03
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
||
|
WHO-ATC |
A03AA03
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
||
|
WHO-ATC |
A03DA05
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7046415
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
CHEMBL253592
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
200-202-0
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
SUB06068MIG
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
DB13738
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
472
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
m99
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | Merck Index | ||
|
5902
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
100000081619
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
1182
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
C166637
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
Camylofin
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
340B6Q764V
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | |||
|
20136
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY | RxNorm | ||
|
54-30-8
Created by
admin on Fri Dec 15 17:13:00 UTC 2023 , Edited by admin on Fri Dec 15 17:13:00 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)